WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 14.4 HKD -4% Market Closed
Market Cap: 59.8B HKD
Have any thoughts about
WuXi Biologics (Cayman) Inc?
Write Note

WuXi Biologics (Cayman) Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi Biologics (Cayman) Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
WuXi Biologics (Cayman) Inc
HKEX:2269
Selling, General & Administrative
-ÂĄ2.4B
CAGR 3-Years
-33%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Selling, General & Administrative
-ÂĄ3.7B
CAGR 3-Years
-12%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Selling, General & Administrative
-ÂĄ1.9B
CAGR 3-Years
-30%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Selling, General & Administrative
-ÂĄ929.9m
CAGR 3-Years
-14%
CAGR 5-Years
-18%
CAGR 10-Years
-24%
M
MGI Tech Co Ltd
SSE:688114
Selling, General & Administrative
-ÂĄ1.3B
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Selling, General & Administrative
-ÂĄ117.2m
CAGR 3-Years
-141%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi Biologics (Cayman) Inc
Glance View

Market Cap
59.8B HKD
Industry
Life Sciences Tools & Services

WuXi Biologics (Cayman) Inc. is a leading global provider of biologics development and manufacturing solutions, operating at the intersection of healthcare innovation and advanced biotechnology. Founded in 2010, the company has rapidly transformed from a local player into a dominant force that serves pharma and biotech firms worldwide. WuXi Biologics offers a comprehensive suite of services, including cell line development, process development, clinical manufacturing, and commercial production of biologics, helping its partners bring life-saving therapies to market with speed and efficiency. With a robust pipeline of collaborations and a commitment to excellence, WuXi is strategically positioned to capitalize on the growing demand for biologics, particularly in the realms of monoclonal antibodies and gene therapies. For investors, WuXi Biologics represents a compelling opportunity in the rapidly evolving biopharmaceutical landscape. The company’s expansive global network, which includes state-of-the-art facilities in China, Europe, and the United States, allows it to meet rising demand while maintaining high-quality standards. WuXi is well-supported by a solid financial foundation, marked by impressive revenue growth and a strong balance sheet. As regulatory frameworks become more favorable and the biopharma industry continues to innovate, WuXi Biologics stands poised to drive sustainable long-term growth, making it an appealing consideration for investors looking to tap into the promising future of medical therapies.

Intrinsic Value
33.71 HKD
Undervaluation 57%
Intrinsic Value
Price

See Also

What is WuXi Biologics (Cayman) Inc's Selling, General & Administrative?
Selling, General & Administrative
-2.4B CNY

Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Selling, General & Administrative amounts to -2.4B CNY.

What is WuXi Biologics (Cayman) Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-47%

Over the last year, the Selling, General & Administrative growth was -22%. The average annual Selling, General & Administrative growth rates for WuXi Biologics (Cayman) Inc have been -33% over the past three years , -47% over the past five years .

Back to Top